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OBJECTIVE: Although possible implications of nitric oxide
in the pathophysiology of liver cirrhosis have been exten-
sively studied, until now few articles have addressed the
assessment of nitric oxide production in primary biliary
cirrhosis. This study was directed to evaluate circulating
nitrosyl-hemoglobin levels as well as neutrophil elastase
and soluble adhesion molecule concentrations in this con-
dition, by assuming these parameters as possible markers of
either inflammatory response or neutrophil activation.
METHODS: Laboratory investigations were performed in 30
patients with primary biliary cirrhosis, in 13 patients with
postviral and/or alcoholic cirrhosis, and in a group of eight
subjects with chronic hepatitis.
RESULTS: Although no difference was detected with respect
to chronic hepatitis subjects, higher levels of nitrosyl-he-
moglobin adducts were found in primary biliary cirrhosis
patients than in postviral or alcoholic cirrhotics and in
normal subjects (3.55 6 1.75 arbitrary units vs 1.95 6 0.57
and 0.84 6 0.34, p 5 0.0004 and p , 0.0001, respectively).
Similarly, more elevated concentrations of neutrophil elas-
tase (213.7 6 192.0 mg/L vs 51.1 6 34.3 and 38.0 6 11.5,
p , 0.0001 and p , 0.0001, respectively) as well as of
soluble forms of intercellular adhesion molecule 1 and en-
dothelial-leukocyte adhesion molecule 1 were shown in
primary biliary cirrhosis patients than in subjects with cir-
rhosis of other etiologies and in controls.
CONCLUSIONS: Highly enhanced nitric oxide production in
primary biliary cirrhosis could be related to the development
of strong inflammation and at least partially to neutrophil
activation, thus suggesting a putative role of these cellular
mediators in the development of liver damage owing to their
ability to synthesize and release a wide variety of important
factors, including elastase and nitric oxide. (Am J Gastro-
enterol 2001;96:869–875. © 2001 by Am. Coll. of Gastro-
enterology)
INTRODUCTION
Although the etiology of primary biliary cirrhosis (PBC)
still remains to be clarified, both cellular and humoral mech-
anisms have been implicated in the progressive nonsuppu-
rative destruction of small intrahepatic bile ducts as well as
in the portal necroinflammation typically associated with
this disorder (1). Indeed, cytokines and cell surface mole-
cules may be involved in local adhesion and activation of
leukocytes at the inflammatory sites (2). In particular, the
sequence of changes affecting portal tracts and bile ducts
appears to be regulated by the aberrant or increased expres-
sion of adhesion molecules (3). It has been demonstrated
that intercellular adhesion molecule 1 (ICAM-1) is strongly
and diffusely expressed during both acute and chronic liver
inflammation including PBC (4–6). Accordingly, increased
circulating levels of the soluble form of ICAM-1 (sICAM-1)
have been shown in a number of inflammatory liver disor-
ders (7, 8), suggesting their usefulness in monitoring disease
progression as well as effects of therapies (9, 10). In addi-
tion to ICAM-1, endothelial leukocyte adhesion molecule 1
or E-selectin has also been found to be expressed in in-
flamed tissues predominantly in the early phase after induc-
tion with various cytokines (11, 12). However, the origin
and possible implications of the soluble form of E-selectin
(sE-selectin) are less well characterized. Both adhesion mol-
ecules may be involved in the migration and activation of
polymorphonuclear neutrophils (PMNs) to sites of bile duct
damage in PBC (3). Among leukocytes involved in changes
affecting portal tracts and bile ducts in PBC, neutrophils
may play a role by releasing highly reactive species and
strong proteases. PMN-mediated responses are generally
attributed to the coordinated effects of reactive oxidative
species and proteolytic enzymes (13). Neutrophil elastase is
the most potent among these latter and has been established
as a highly specific and reliable index of in vivo neutrophil
activation (14). Besides reactive oxygen intermediates, hu-
man neutrophils have been demonstrated to be capable of
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synthesizing and releasing nitric oxide (NO) (15, 16), a
versatile multifunctional molecule acting as both a protec-
tive and a toxic mediator (17, 18). Its production has been
hypothesized to be altered in different pathophysiological
conditions of the liver, such as cirrhosis and its complica-
tions (19, 20).
This study was undertaken to determine NO production,
assessed by measuring circulating nitrosyl-hemoglobin ad-
ducts and serum neutrophil elastase, as an indirect marker of
PMN leukocyte activation, in patients affected by PBC and
in two groups of subjects with chronic hepatitis and post-
viral and/or alcoholic cirrhosis. We also looked at possible
relationships of these parameters with soluble forms of
ICAM-1 and E-selectin and with liver biochemical tests.
MATERIALS AND METHODS
Subjects
Thirty consecutive patients (mean age 53.3 yr, range 25–
77), 26 female and four male, with PBC were studied. All
had positive antimitochondrial antibody testing, and PBC
was diagnosed an average of 39.9 months (range 1–146
months) before entering the study on the basis of both
typical biochemical patterns and histopathological findings.
At the time of diagnosis 13 patients were in stage I, four in
stage II, 10 in stage III, and three in stage IV according to
conventional criteria (21). Laboratory data as well as the
prognostic Mayo score (22) at entry are shown in Table 1;
viral markers were negative in all patients. Symptoms re-
ferrable to liver disease such as fatigue and pruritus were
reported by 25 of the studied patients, whereas 19 presented
with extrahepatic autoimmune disorders, including
Sjo¨gren’s syndrome, arthropathies, Raynaud’s phenome-
non, and thyroid dysfunction. Esophageal varices with or
without previous hemorrhage were documented in 10 cases.
Substitutive bile salt therapy (12–15 mg/kg/day of ursode-
oxycholic acid) was being administered in 15 patients at the
time of the study, and only four were taking corticosteroids
and/or immunosuppressives (5–15 mg/day of prednisone for
three and 100 mg/day of azathioprine for one). A group of
eight patients (mean age 44.7 yr, range 39–53), two female
and six male, with biopsy-proven chronic hepatitis (CH) (B
virus infection in five and C virus in the remaining three)
was also enrolled. Thirteen patients (mean age 48.1 yr,
range 26–62; two female and 11 male) with cirrhosis of
diverse etiology (seven postviral hepatitis C, three postviral
hepatitis B and C, and three alcoholic) and portal hyperten-
sion served as a reference group. An additional cohort
including 10 patients with choledocholithiasis (mean age 62
yr, range 36–85; seven female and three male) was also
studied. Informed written consent was obtained for each
patient, and the study was performed according to the eth-
ical guidelines of the 1975 Declaration of Helsinki.
NO Determination
NO production was assessed directly as nitrosyl-hemoglo-
bin complexes. The binding of NO to the heme iron of
deoxyhemoglobin, mainly on the venous side of the circu-
lation, leads to the formation of stable nitrosyl-hemoglobin
adducts (23, 24). These NO-containing compounds function
as either carrier or store systems for NO released into the
bloodstream by several cellular sources (25). Due to the
unpaired electron residing on NO, nitrosyl-heme adducts
may interact with a magnetic field, i.e., they are paramag-
netic. With this property, the technique of electron para-
magnetic resonance (EPR) spectroscopy has been used to
detect circulating NO-hemoglobin derivatives as means to
study the in vivo generation of NO (26). EPR spectra were
recorded with heparinized whole blood samples. The quan-
titative analysis of characteristic EPR signals was carried
out by double integration of typical triplet patterns centered
at a spectroscopic splitting factor of 2.015 with 15.6 Gauss
line widths. In each case the magnitude of the EPR peaks
was considered to be proportional to the amounts of ni-
trosyl-hemoglobin adducts. Because of the unavailability of
a reliable standard for these nitrosyl-hemoglobin com-
Table 1. Laboratory Data of Primary Biliary Cirrhosis Patients (n 5 30)
Variable Mean Value 6 SD Minimum Value Maximum Value Normal Range
AST (IU/L) 75.6 6 44.2 21 188 0–31 (women)
0–37 (men)
ALT (IU/L) 79.8 6 56.2 14 279 0–31 (women)
0–37 (men)
ALP (IU/L) 513.2 6 406.2 87 1679 40–145
GGT (IU/L) 275.3 6 236.7 38 1118 8–35 (women)
10–50 (men)
TB (mg/dl) 1.3 6 1.2 0.3 4.5 0.2–1.0
DB (mg/dl) 0.7 6 0.9 0.1 3.6 0–0.2
ALB (g/dl) 4.0 6 0.6 2.0 4.9 3.6–5.2
PT (INR) 0.96 6 0.20 0.83 1.45 0.85–1.25
IgG (mg/dl) 1526.0 6 516.2 200 2840 840–1660
IgA (mg/dl) 275.2 6 95.0 93 530 90–395
IgM (mg/dl) 403.5 6 225.0 113 919 48–220
Mayo score 4.49 6 1.39 2.51 8.43
AST 5 aspartate amino-transferase; ALT 5 alanine amino-transferase; ALP 5 alkaline phosphatase; GGT 5 g-glutamyl transpeptidase; TB 5 total bilirubin; DB 5 direct
bilirubin; ALB 5 albumin; PT 5 prothrombin time; INR 5 International Normalized Ratio; Ig 5 immunoglobulins.
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plexes, results were expressed in arbitrary units (AUs) as
calculated by the instrument software from the area under
the three-line EPR spectra. Intra- and extra-assay variations,
calculated on seven replicates in a 1-day experiment and on
10 replicates over a 30-day period, were 7.3% and 14.7%,
respectively. Nitrosyl-hemoglobin spectra from specimens
stored at 280°C appeared stable for at least 2 months.
Neutrophil Elastase Measurement
The content of neutrophil elastase in serum samples was
determined by a homogeneous immunoenzymatic assay
based on the agglutination of latex particles in the presence
of elastase–a1-protease inhibitor complexes. This method
(Ecoline, Merck, Darmstadt, Germany) has been applied to
an automated analyzer (Merck Mega), yielding 2.6% and
6.7% variations in intra- and extra-assay replicates, respec-
tively. Reference values (29–86 mg/L) indicated by the
purchasing company did not significantly differ from those
observed in a group of healthy volunteers in our laboratory.
Soluble ICAM-1 and E-Selectin Concentrations
Two photometric one-step “sandwich” enzyme immunoas-
says were used for the quantification of human sICAM-1
and E-selectin (Boehringer Mannheim, Mannheim, Ger-
many) in serum samples. Intra- and interassay variances
were 6.6% and 13.4% for sICAM-1 and 8% and 15% for
sE-selectin, according to manufacturer indications. No
cross-reaction with serum components other than the solu-
ble forms of the adhesion molecules has been found for each
assay kit. Normal values as indicated by the manufacturer
did not differ with respect to findings in our experience with
healthy volunteers and were assumed to be reliable controls.
Morphological Evaluations
Needle liver biopsies performed close to the time of blood
withdrawal for the biochemical measurements included in
this study were available from 17 PBC patients. The degree
of neutrophil infiltration of liver biopsies was evaluated on
5-mm-thick sections from tissue fixed in neutral buffered
4% formaldehyde solution, dehydrated in graded ethanol
and then embedded in paraffin. The sections were stained
with the naphtol AS-D chloroacetate esterase technique as
described by Moloney et al. (27) with slight modifications,
where the substrate was dissolved in dimethyl sulphoxide/
Triton X-100 (9:1, vol/vol). Fast garnet GBC, a diazonium
salt, was used as a pair for the naphtol released by the action
of the esterase specifically present in the neutrophils. Fi-
nally, the sections were counterstained with Harris hema-
toxylin, thereby providing a greenish background against
which the neutrophils appeared red.
Statistical Analysis
Differences between PBC patients and the other studied
groups as well as within the PBC group were evaluated by
Student’s t test. Spearman rank analysis was performed to
assess correlations among considered parameters. In each
case a p value of ,0.05 was assumed to be statistically
significant.
RESULTS
Increased amounts of EPR-detectable circulating nitrosyl-
hemoglobin adducts were found in PBC with respect to
cirrhotic patients and controls (3.55 6 1.75 AUs vs 1.95 6
0.57 and 0.84 6 0.34, p 5 0.0004 and p , 0.0001, respec-
tively), whereas no significant difference was shown be-
tween PBC and CH subjects (Fig. 1). It is noteworthy that
higher nitrosyl-hemoglobin levels were detected in PBC
patients than in lithiasis subjects (1.24 6 0.38, p , 0.0001).
Furthermore, a superimposable behavior was observed for
soluble adhesion molecules: both were elevated in PBC
Figure 1. Nitric oxide levels measured in 30 patients with PBC, as
compared to those detected in eight subjects with CH, 13 with
postviral and/or alcoholic cirrhosis, eight normal healthy volun-
teers, and 10 patients with choledocholithiasis. Student’s t test p
values for pairwise comparisons were CH vs cirrhosis, not signif-
icant; CH vs controls, p 5 0.006; CH vs lithiasis, p 5 0.02;
cirrhosis vs controls, p 5 0.0005; cirrhosis vs lithiasis, p 5 0.008;
controls vs lithiasis, p 5 0.04. F 5 single values; lines 5 mean
values for each of the five groups of subjects.
Figure 2. Individual and mean values of sICAM-1 (A) and sE-
selectin (B): findings in 30 PBC patients, eight CH subjects, 13
postviral and/or alcoholic cirrhotics, and eight healthy controls.
Pairwise comparisons by Student’s t test yielded the following p
values: CH vs cirrhosis, p 5 0.015 and p 5 0.003 for sICAM-1 and
sE-selectin, respectively; CH vs controls, p 5 0.0004 and p 5
0.008; cirrhosis vs controls, p 5 0.0008 and not significant.
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patients in comparison to cirrhotics and controls [1375.7 6
939.7 ng/ml vs 560 6 282.3 and 213.3 6 55.3, p 5 0.0001
and p , 0.0001, respectively, for sICAM-1 (Fig. 2A);
18.9 6 12.7 ng/ml vs 4.1 6 4.9 and 7.9 6 5.5, p , 0.0001
and p 5 0.0011, respectively, for sE-selectin (Fig. 2B)] but
similar to levels detected in CH subjects. Nevertheless,
sICAM-1 and sE-selectin findings were not correlated in our
study population. On the other hand, the concentrations of
neutrophil elastase were significantly increased in PBC pa-
tients only (213.7 6 192.0 mg/l vs 51.1 6 34.3 and 38.0 6
11.5 in controls and in cirrhotic patients, respectively; p ,
0.0001 for both comparisons), whereas they did not differ
among CH subjects, cirrhotics, and controls (Fig. 3). Neither
gender nor age differences were found for all considered
parameters.
sICAM-1 and sE-selectin levels were unaffected by hy-
drophylic bile salt administration (1368.7 6 777.5 ng/ml in
patients who were given this therapy vs 1382.7 6 1106.5 in
those who were not undertaking any treatment for at least 6
months preceding the study, p 5 0.97, and 18.7 6 14.4
ng/ml vs 19.0 6 10.7, p 5 0.94, respectively). Similarly,
substitutive therapy did not influence NO production
(3.53 6 1.94 AUs vs 3.34 6 1.62, p 5 0.76) or neutrophil
elastase release (197.0 6 183.0 mg/L vs 230.3 6 205.6, p 5
0.64).
Interestingly, 10 patients who had portal hypertension and
a history of esophageal varices with or without previous
hemorrhage had lower nitrosyl-hemoglobin levels and neu-
trophil elastase concentrations as compared to the other 20
patients (2.65 6 1.23 AUs vs 3.81 6 1.87, p , 0.05, and
115.5 6 112.0 mg/L vs 262.7 6 206.7, p 5 0.0174, respec-
tively).
In Figure 4 results of correlations reaching statistical
significance among studied parameters and biochemical fea-
tures in the group of all PBC patients are reported.
Figure 3. Neutrophil elastase results from 30 PBC patients com-
pared to those detected in eight CH and 13 cirrhotic patients, as
well as eight healthy controls. Individual and mean values are
indicated. Student’s t test p values for pairwise comparisons were
CH vs cirrhosis, not significant; CH vs controls, not significant;
cirrhosis vs controls, not significant.
Figure 4. Statistically significant Spearman rank correlations
among studied parameters in patients with primary biliary cirrho-
sis. (A) Correlations between nitrosyl-hemoglobin levels and AST
as well as g-glutamyl transpeptidase (GGT) values. (B) Correla-
tions between sE-selectin levels and total bilirubin (TB) as well as
direct bilirubin (DB) values. (C) Correlations between sICAM-1
and AST, alkaline phosphatase (ALP), TB, DB, and IgM.
872 Battista et al. AJG – Vol. 96, No. 3, 2001
The morphological assessment revealed the presence of a
variable number of neutrophils infiltrating the portal tracts
in all observed specimens but one (Fig. 5). Neutrophil
infiltrates ranged from scarce and isolated to some cases
where they appeared as the most represented cell types, with
a reproducible correlation between the degree of neutrophil
accumulation, though qualitatively assessed, and both ni-
trosyl-hemoglobin and neutrophil elastase levels.
DISCUSSION
In agreement with previous reports (28, 29), we have found
that serum concentrations of soluble forms of ICAM-1 and
E-selectin are significantly elevated in PBC patients relative
to normal subjects. Although similar to levels measured in
CH subjects, in PBC they are highly increased as compared
to those detected in cirrhotic patients. This may reflect
upregulated expression of adhesion molecules on bile ducts,
hepatocytes, vascular endothelial cells, and infiltrating leu-
kocytes, a critical step in the pathogenesis of immune-
mediated destruction of interlobular bile ducts and hepato-
cytes (3, 6). Although not specific to PBC, increased serum
levels of circulating forms of adhesion molecules have been
correlated with the stage of progression of the disease (9, 10,
29). Indeed, this is supported by relationships between sol-
uble adhesion molecules and biochemical markers of cho-
lestasis in our study. Both adhesion molecules included in
this work are capable of enhancing PMN recruitment to sites
of inflammatory damage (30, 31). sICAM-1 has been shown
to induce elastase release by PMNs and to participate as a
priming stimulus in the production of reactive oxygen spe-
cies in response to a second activating effector substance
(32). On the other hand, E-selectin is particularly important
in the early adhesion and rolling of neutrophils (33, 34).
From these observations, it could be hypothesized that ex-
tremely high sICAM-1 and sE-selectin amounts measured
though nonspecific tests of neutrophil responses may reflect
an enhanced PMN activation in PBC, as demonstrated by
our findings of elevated neutrophil elastase concentrations
mainly in this group of patients. Among reactive molecules,
human neutrophils are capable also of releasing NO. The
greatly augmented levels of circulating nitrosyl-hemoglobin
adducts detected in our study suggest that an enhanced NO
production by these as well as by other cell types may occur
in PBC. Till now, few articles have addressed the determi-
nation of circulating NO in PBC patients; yet hyperproduc-
Figure 5. (A, B) PBC stages I–II. Portal tract expanded by granulomatous inflammation in which numerous red-stained neutrophils are
visible. A, 3200; B, 3400. (C, D) PBC stages III–IV. Bridging fibrosis between portal tracts accompanied by a moderate infiltrate of
lymphocytes, macrophages, and occasional plasma cells. Neutrophils appear as red-stained cells diffusely distributed. C, 3200; D, 3400.
AS-D chloroacetate counterstained with Harris hematoxylin.
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tion of NO, considered by many authors a feature of cir-
rhosis and chronic liver disease per se, seems to be highly
upregulated in PBC. EPR-detectable nitrosyl-hemoglobin
complexes are useful in assessing NO synthesis, and their
increased levels may be directly related to NO biological
effects (24). Although an ubiquitously enhanced NO gen-
eration is likely to occur in PBC from a variety of cellular
sources including Kupffer cells, endothelial cells, and leu-
kocytes, from our results one can suppose that activated
neutrophils in this condition release relatively large amounts
of NO. Several mechanisms may account for the enhanced
NO production by neutrophils, including cytokine-mediated
stimulation of inducible NO synthase (15) and adherence-
dependent activation as demonstrated for hydrogen peroxide
(35). Cholestasis itself may induce the upregulation of NO
synthetic pathways and/or the release of the mediator (36,
37). It should be considered that, even if large duct obstruc-
tion could be associated with cholangiolitis and neutrophil
infiltration, the duration of the disease in our lithiasis con-
trols, always longer than 1 yr, may favor the hypothesis that
in all of them cholestasis was acutely precipitated by stones,
a condition presumably not accompanied by neutrophil ac-
tivation and NO production. The systemic activation of
neutrophils is not the entire explanation, as demonstrated by
the lack of a significant correlation between nitrosyl-hemo-
globin and neutrophil elastase levels, thus suggesting dif-
ferent sources and/or different modulation. Nevertheless, a
complex series of NO/neutrophil interactions may condition
liver cell injury in the pathogenesis of PBC. On one hand,
NO participates in the generation of strong oxidants from
neutrophils through its reactions with reactive oxygen spe-
cies and myeloperoxidase and contributes to the reduction in
antiproteinase activity (38). On the other hand, it exerts
protective and anti-inflammatory effects at least in part by
preventing neutrophil adhesion and modulating neutrophil
responses (39). This may be supported by our findings of an
inverse correlation between nitrosyl-hemoglobin levels and
the Mayo score in a population of 45 PBC patients including
15 subjects in addition to those enrolled in this study (rs 5
0.31, p 5 0.04 by Spearman rank test) (40) as well as of the
occurrence of lower nitrosyl-hemoglobin levels in patients
with portal hypertension.
Due to the cross-sectional nature of this study, effects of
substitutive treatment cannot be substantiated even if no
differences were found between the group of patients who
were undertaking this kind of therapy and the nontreatment
group. However, our data seem to indicate that substitutive
bile salts have no influence on biochemical markers of either
neutrophil activation or cellular adhesion.
Whether the expression of adhesion molecules and the
release of soluble mediators are an early event in the patho-
genesis of bile duct damage or a secondary response to
inflammation is not readily deducible from our results.
Changes affecting vascular and infiltrating cells in the portal
tract could be related to the inflammatory process itself, and
abnormalities of neutrophil functions have been described in
cirrhosis and cholestasis as a consequence rather than a
cause of the liver disease (41). Despite limitations of the
measurement of systemic markers, however, it should be
noted that neutrophil infiltrates are present in the liver in the
majority of PBC biopsies in our study population, with a
good correlation between the degree of neutrophil accumu-
lation and circulating levels of assessed mediators. From our
findings it can be suggested that, once recruited and primed
due to the intervention of cell adhesion molecules, neutro-
phils may mediate a wide variety of functions by releasing
a number of important effector substances, including NO
and elastase. In addition to neutrophils, several different
cells are likely to be involved in the generation of NO as
well as other soluble factors, thereby triggering and sustain-
ing the chronic inflammatory process of PBC.
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